155 related articles for article (PubMed ID: 25720397)
1. An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/Aβ1-42 Ratio in ApoE4-Negative Mild Cognitive Impairment Patients.
Sun Y; Bresell A; Rantalainen M; Höglund K; Lebouvier T; Salter H;
J Alzheimers Dis; 2015; 45(4):1061-76. PubMed ID: 25720397
[TBL] [Abstract][Full Text] [Related]
2. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
[TBL] [Abstract][Full Text] [Related]
3. Association of MAPT haplotype-tagging polymorphisms with cerebrospinal fluid biomarkers of Alzheimer's disease: A preliminary study in a Croatian cohort.
Babić Leko M; Willumsen N; Nikolac Perković M; Klepac N; Borovečki F; Hof PR; Sonicki Z; Pivac N; de Silva R; Šimić G
Brain Behav; 2018 Nov; 8(11):e01128. PubMed ID: 30329219
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal Fluid Alzheimer's Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment.
Sun Y; Moghekar A; Soldan A; Pettigrew C; Greenberg B; Albert M; Wang MC;
J Alzheimers Dis; 2023; 96(1):287-300. PubMed ID: 37742656
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504
[TBL] [Abstract][Full Text] [Related]
6. Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.
Michaud TL; Kane RL; McCarten JR; Gaugler JE; Nyman JA; Kuntz KM;
J Alzheimers Dis; 2015; 47(3):729-40. PubMed ID: 26401707
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI.
Toledo JB; Xie SX; Trojanowski JQ; Shaw LM
Acta Neuropathol; 2013 Nov; 126(5):659-70. PubMed ID: 23812320
[TBL] [Abstract][Full Text] [Related]
8. Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum.
Marshall GA; Lorius N; Locascio JJ; Hyman BT; Rentz DM; Johnson KA; Sperling RA
J Alzheimers Dis; 2014; 41(3):719-28. PubMed ID: 24685624
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer's Disease Biomarkers.
Blanco-Cantó ME; Monge-Argilés JA; Pérez-Cejuela C; Badía C; Gabaldón L; Muñoz-Ruíz C; Sánchez-Payá J; Gasparini-Berenguer R; Leiva-Santana C
Am J Alzheimers Dis Other Demen; 2017 Mar; 32(2):101-107. PubMed ID: 28191798
[TBL] [Abstract][Full Text] [Related]
10. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
Sun X; Dong C; Levin B; Crocco E; Loewenstein D; Zetterberg H; Blennow K; Wright CB;
Alzheimers Dement; 2016 Nov; 12(11):1159-1166. PubMed ID: 27321472
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status.
Rehman H; Ang TFA; Tao Q; Espenilla AL; Au R; Farrer LA; Zhang X; Qiu WQ;
J Alzheimers Dis; 2024; 97(2):621-633. PubMed ID: 38143358
[TBL] [Abstract][Full Text] [Related]
12. Neurodegenerative disease biomarkers Aβ
Chen JA; Fears SC; Jasinska AJ; Huang A; Al-Sharif NB; Scheibel KE; Dyer TD; Fagan AM; Blangero J; Woods R; Jorgensen MJ; Kaplan JR; Freimer NB; Coppola G
Brain Behav; 2018 Feb; 8(2):e00903. PubMed ID: 29484263
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages.
Chung J; Wang X; Maruyama T; Ma Y; Zhang X; Mez J; Sherva R; Takeyama H; ; Lunetta KL; Farrer LA; Jun GR
Alzheimers Dement; 2018 May; 14(5):623-633. PubMed ID: 29274321
[TBL] [Abstract][Full Text] [Related]
14. NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.
Soldan A; Oh S; Ryu T; Pettigrew C; Zhu Y; Moghekar A; Xiao MF; Pontone GM; Albert M; Na CH; Worley P
Ann Neurol; 2023 Oct; 94(4):620-631. PubMed ID: 37345460
[TBL] [Abstract][Full Text] [Related]
15. Novel Genetic Variants in TP37, PIK3R1, CALM1, and PLCG2 of the Neurotrophin Signaling Pathway Are Associated with the Progression from Mild Cognitive Impairment to Alzheimer's Disease.
Li H; Liu H; Lutz MW; Luo S;
J Alzheimers Dis; 2023; 91(3):977-987. PubMed ID: 36530083
[TBL] [Abstract][Full Text] [Related]
16. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative.
Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K
Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's disease CSF biomarkers: clinical indications and rational use.
Niemantsverdriet E; Valckx S; Bjerke M; Engelborghs S
Acta Neurol Belg; 2017 Sep; 117(3):591-602. PubMed ID: 28752420
[TBL] [Abstract][Full Text] [Related]
18. Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Ingannato A; Crucitti C; Bagnoli S; Padiglioni S; Romano L; Galdo G; Emiliani F; Frigerio D; Ferrari C; Moschini V; Morinelli C; Notarelli A; Sorbi S; Nacmias B; Bessi V
Sci Rep; 2024 May; 14(1):11307. PubMed ID: 38760423
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer disease pathology and the cerebrospinal fluid proteome.
Dayon L; Núñez Galindo A; Wojcik J; Cominetti O; Corthésy J; Oikonomidi A; Henry H; Kussmann M; Migliavacca E; Severin I; Bowman GL; Popp J
Alzheimers Res Ther; 2018 Jul; 10(1):66. PubMed ID: 30021611
[TBL] [Abstract][Full Text] [Related]
20. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts.
Lantero-Rodriguez J; Vrillon A; Fernández-Lebrero A; Ortiz-Romero P; Snellman A; Montoliu-Gaya L; Brum WS; Cognat E; Dumurgier J; Puig-Pijoan A; Navalpotro-Gómez I; García-Escobar G; Karikari TK; Vanmechelen E; Ashton NJ; Zetterberg H; Suárez-Calvet M; Paquet C; Blennow K
Alzheimers Res Ther; 2023 Mar; 15(1):48. PubMed ID: 36899441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
